Biomedicine industries inject vigor into Daxing's growth

In the first three quarters of this year, the GDP of Beijing's Daxing district reached 107 billion yuan ($16.77 billion), a year-on-year increase of 69.8 percent. Its growth rate ranks first among all districts in Beijing. 

The biomedicine industry has played a strong role. Sinovac Life Sciences Co, whose vaccines have been listed by the World Health Organization for emergency use, has achieved an annual production capacity of 2 billion doses.

Industrial agglomeration saw a trend continuing this year. A biomedical incubator program, located in the comprehensive bonded zone of Beijing Daxing International Airport (Phase 1) started construction recently. First-stage construction is expected to wrap up in 2023.

A series of pharmaceutical companies, such as Mab Works and Jiuzhitang Maker, have settled in the district. Many medical R&D centers have signed contracts with Daxing, including the Beijing institute of BGI Group.

The district has rolled out dozens of favorable policies and large subsidies to assist its pharmaceutical industry. These measures have supported the research and development of innovative drugs with global patents and the creation of a new industrial ecosystem.